Some Connecticut Residents May Soon Get 2nd COVID Booster

CONNECTICUT — As COVID-19 rates decline in Connecticut, people 65 and older may soon be able to get a second COVID-19 vaccine booster to increase the durability of their coronavirus vaccinations.

Pfizer and its coronavirus vaccine partner, BioNTech, have asked the Food and Drug Administration for emergency use authorization for the shots in an effort to bolster immunity among older Americans.

COVID-19 infection rates have declined significantly in the last month. The seven-day average of cases Wednesday was about 30,500 nationwide, compared with about 129,250 on Feb. 16, according to a database kept by The New York Times.

Health officials are optimistic as the third year of the pandemic begins, couching that with concern about an increase in so-called stealth omicron cases around the country. The omicron subvariant BA.2 has grown more common in the two months since it was first detected in the United States in January, and now represents about a quarter of new cases, according to the U.S. Centers for Disease Control and Prevention.

The number of Connecticut residents hospitalized with the virus has dropped like a stone since the second week in January.

Yesterday, the state Department of Public Health reported COVID hospitalizations fell below 100 for the first time since last July. Today, the number of beds reportedly filled with coronavirus patients regained some ground, and sits at 100 even.

The coronavirus alert level in nearly every Connecticut municipality continues to drop. Less than 10 communities are "red zones," reporting the highest coronavirus alert level, according to DPH.

The color codes correspond to guidance from DPH. Populations in the red zone have reported 15 or more cases per 100,000 people over a two-week average.

The number of COVID-19 cases among Connecticut PK-12 students has declined significantly since its mid-January high, but rose slightly in this week's report from the Department of Public Health.

On Wednesday, DPH reported 721 total infections for students, up from 616 last week. The state logged 148 positive COVID-19 cases among school staff, down from 155 the previous week.

Cases among staff and students had remained relatively low until the first week of November, when they began their climb. Confirmed cases among both groups shot up dramatically after the first of the year.

Pfizer-BioNTech said the request for FDA authorization of a second booster is based on “real-world” data from studies in Israel, which is among a handful of countries that offer the second boosters to older people.

Those studies showed confirmed infections were two times lower and rates of severe illness were four times lower among people who received the second Pfizer booster, compared to people who received only one, according to a press release.

Moderna, which also makes a two-shot mRNA vaccine and booster, hasn’t asked the FDA for approval of a fourth shot in the series, but Stephane Bancel, the company’s chief executive, said at a health care conference in January that he thinks more boosters will be necessary.

Moderna is continuing its bivalent omicron-specific booster trial, which uses an omicron-specific booster and the COVID-19 vaccine.

“Our goal has been to remain ahead of the virus, and we are committed to generating and sharing data with public health authorities as they prepare for the fall booster season,” Moderna CEO Stéphane Bancel said in a news release.

COVID-19 money was pulled from the $1.5 trillion omnibus spending bill approved last week, leaving President Joe Biden’s coronavirus road map in some doubt. Some Biden officials have said they believe all adults should get a second booster, regardless of age, as immunity wanes.

The FDA will convene its outside advisory committee in April to discuss whether COVID-19 booster shots should be part of the annual influenza vaccine campaign encouraging all Americans to get their shots in the fall, ahead of cold-weather season when people are cooped up inside, The Washington Post reported.